We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+3.56%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$14.4B
AUM Growth
+$2.13B
Cap. Flow
+$2.21B
Cap. Flow %
15.31%
Top 10 Hldgs %
53.56%
Holding
108
New
27
Increased
43
Reduced
13
Closed
22

Top Buys

Rank Stock Value
1
COL
Rockwell Collins
COL
+$391M
2
MON
Monsanto Co
MON
+$386M
3
KDP icon
Keurig Dr Pepper
KDP
+$362M
4
LOGM
LogMein, Inc.
LOGM
+$212M
5
TFCF
Twenty-First Century Fox, Inc. Class B
TFCF
+$182M

Top Sells

Rank Stock Value
1
TWX
Time Warner Inc
TWX
+$306M
2
AABA
Altaba Inc
AABA
+$248M
3
BUD icon
AB InBev
BUD
+$164M
4
CPN
Calpine Corporation
CPN
+$163M
5
HUN icon
Huntsman Corp
HUN
+$80.7M

Sector Composition

Rank Sector Weight
1 Technology 21.51%
2 Healthcare 15.68%
3 Communication Services 13.68%
4 Financials 11.37%
5 Industrials 10.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAVM
26
DELISTED
Cavium, Inc.
CAVM
$150M 1.04%
1,890,000
+1,710,000
+950% +$149M
LBTYK icon
27
Liberty Global Class C
LBTYK
$3.55B
$149M 1.03%
4,898,093
+795,970
+19% +$26.4M
LBTYA icon
28
Liberty Global Class A
LBTYA
$3.63B
$148M 1.02%
4,713,926
+1,443,746
+44% +$49.9M
FIS icon
29
Fidelity National Information Services
FIS
$21.3B
$147M 1.02%
1,527,538
-503,838
-25% -$49.4M
RDUS
30
DELISTED
Radius Health, Inc.
RDUS
$147M 1.02%
4,086,300
+150,000
+4% +$5.42M
GILD icon
31
Gilead Sciences
GILD
$181B
$137M 0.95%
+1,820,000
New +$145M
ABLX
32
DELISTED
Ablynx NV
ABLX
$134M 0.93%
2,450,000
+100,000
+4% +$4.96M
AZN icon
33
AstraZeneca
AZN
$257B
$125M 0.86%
1,782,500
-100,000
-5% -$6.93M
PPLI
34
People Inc
PPLI
$2.86B
$112M 0.77%
+4,000,716
New +$105M
TWX
35
DELISTED
Time Warner Inc
TWX
$96.5M 0.67%
1,020,000
-3,245,000
-76% -$306M
BIIB icon
36
Biogen
BIIB
$32B
$93.1M 0.64%
340,000
-200,000
-37% -$62.1M
ASND icon
37
Ascendis Pharma A/S
ASND
$16.6B
$84.2M 0.58%
+1,286,800
New +$72.3M
KYNB
38
Kyntra Bio
KYNB
$30.4M
$79.3M 0.55%
68,700
+2,400
+4% +$3.16M
XL
39
DELISTED
XL Group Ltd.
XL
$74.9M 0.52%
+1,355,000
New +$59.5M
ENTA icon
40
Enanta Pharmaceuticals
ENTA
$392M
$74M 0.51%
915,000
-10,000
-1% -$770K
ESRX
41
DELISTED
Express Scripts Holding Company
ESRX
$71.8M 0.5%
+1,040,000
New +$79.3M
SAGE
42
DELISTED
Sage Therapeutics
SAGE
$71.7M 0.5%
445,000
+45,000
+11% +$7.64M
IOVA icon
43
Iovance Biotherapeutics
IOVA
$3.76B
$70.1M 0.49%
4,150,000
+2,283,100
+122% +$34.6M
HRG
44
DELISTED
HRG Group, Inc.
HRG
$66.6M 0.46%
4,040,000
+2,898,000
+254% +$48.4M
ZGNX
45
DELISTED
Zogenix, Inc.
ZGNX
$63.1M 0.44%
1,576,000
+726,000
+85% +$28.8M
XLRN
46
DELISTED
Acceleron Pharma
XLRN
$54.8M 0.38%
1,401,000
+313,000
+29% +$13.3M
QCOM icon
47
Qualcomm
QCOM
$169B
$53.2M 0.37%
960,000
+170,217
+22% +$10.8M
FOLD
48
DELISTED
Amicus Therapeutics
FOLD
$52.4M 0.36%
3,481,000
+700,000
+25% +$10.7M
BG icon
49
Bunge Global
BG
$21.7B
$51M 0.35%
690,000
+585,000
+557% +$44.2M
MYOK
50
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$50.7M 0.35%
1,039,278
+175,546
+20% +$9.13M
1
2
3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2018 Portfolio in Review

As of Q1 2018, Thomas Steyer held 108 positions worth $14.4B, up 17% from $12.3B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Thomas Steyer deployed $2.21B of net new capital in Q1 2018, opening 27 new positions and adding to 43 existing holdings. Its largest new stake was Keurig Dr Pepper: 3,265,800 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was Time Warner Inc, an estimated $306M trimmed.

  • Thomas Steyer's largest Q1 2018 buy was Keurig Dr Pepper: 3,265,800 shares worth $387M.
  • Thomas Steyer added most to Rockwell Collins in Q1 2018, an estimated $391M increase.
  • Thomas Steyer's biggest Q1 2018 reduction was Time Warner Inc, cutting an estimated $306M.
  • Thomas Steyer fully exited AB InBev in Q1 2018, selling an estimated $164M.
  • Thomas Steyer's ten largest holdings make up 54% of its $14.4B portfolio in Q1 2018.
  • Thomas Steyer opened 27 new positions and closed 22 in Q1 2018.
  • Thomas Steyer's portfolio value rose 17% quarter-over-quarter to $14.4B.

Based on Farallon Capital Management's 13F filing for Q1 2018, filed 15 May 2018.